- * Subjects with congenital hemophilia B who completed Study CTAMT-060-01
- * Able to provide informed consent following receipt of verbal and written information about the trial.
Hemophilia B
Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706 | PHASE 2 | OBSERVATIONAL
This is an open-label, extension study enrolling patients who have successfully completed all assessments in Study CT-AMT-060-01 (Years 1-5). Assessment phase will begin at Visit 36 (the first clinical visit in this extension study, approximately 5.5 years after the initial dosing visit Study CT-AMT-060-01) and go to Visit 45 (10-years post-dosing in Study CT-AMT-060-01).
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Vivantes Klinikum im Friedrichshain
Berlin,Germany
Universitaetsklinikum Frankfurt Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt,Germany
Amsterdam UMC Locatie AMC
Amsterdam,Netherlands
Groningen UMC
Groningen,Netherlands
Erasmus MC
Rotterdam,Netherlands
Universitair Medisch Centrum Utrecht
Utrecht,Netherlands
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov